Viking Therapeutics: Analysts Set $95 Price Target – Stock at $28.60
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics (VKTX) closed on August 14, 2026 at $28.60 USD with a minimal gain of 0.18 percent.
- 24 analysts rate the stock predominantly positive: 1 Strong Buy, 22 Buy, 1 Hold – no sell recommendation (as of July 9, 2026).
- The average price target is $93.60 USD with a median of $95 USD – the range extends from $83 to $101 USD.
- The US biotech company is in the pre-revenue phase with a loss per share of -$4.66 USD and a market capitalization of $3.80 billion USD.
- The Relative Strength Index (RSI) stood at 43.78 on August 14 in the neutral range.
Viking Therapeutics Inc. (VKTX) closed on August 14, 2026 at $28.60 USD and recorded a minimal gain of $0.05 from the previous day ($28.55 USD), representing a change of 0.18 percent. The US biotech company's stock is trading well below analyst estimates.
Analyst Ratings: Broad Buy Recommendation
According to data from July 9, 2026, 24 analysts rate Viking Therapeutics stock. The distribution shows a clear trend: 1 analyst rates the stock as "Strong Buy," 22 recommend it for purchase ("Buy"), and only 1 analyst recommends holding ("Hold"). There are no sell recommendations.
The average price target is $93.60 USD, with the median at $95 USD. The range of analyst estimates extends from a low target of $83 USD to a high target of $101 USD. At the current price of $28.60 USD, this represents a calculated upside potential of more than 230 percent to the median price target.
Company Profile and Financial Metrics
Viking Therapeutics is a US-based clinical biotech company focused on developing novel therapies for metabolic and endocrine disorders. The company went public on April 29, 2015 and remains in the pre-revenue phase – no revenues are currently being generated.
The market capitalization amounts to approximately $3.80 billion USD (as of August 14, 2026). The price-to-book ratio (P/B Ratio) stands at 6.22. The loss per share (EPS) is -$4.66 USD. A price-to-earnings ratio (P/E) is not reported due to the lack of profitability.
Technical Indicators and Trading Volume
The Relative Strength Index (RSI) stood at 43.78 on August 14, 2026 – a value in the neutral range that indicates neither an overbought nor oversold market condition. Trading volume on August 14 was 3,575 shares, significantly below the average volume of 1.76 million shares.
The stock reached its 52-week high at $43.15 USD and its low at $22.96 USD. With a beta of 0.60, the stock exhibits lower volatility than the overall market – price fluctuations tend to be more moderate than the broad equity index.
Sector and Market Environment
Viking Therapeutics operates in the biotechnology sector, an area characterized by high development risks and lengthy approval cycles. Companies at this stage are typically dependent on clinical trial results and regulatory decisions, which can lead to increased price volatility. The analyst assessment reflects expectations regarding the success of ongoing development programs.
According to available information, the company is working on the development of therapeutic candidates, including VK2735, a dual GLP-1/GIP receptor agonist. Detailed information regarding current clinical trials or development progress is not available at this time.